Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2026-04-07 16:50:56 ET · period of report 2026-04-06 · accession 0001628280-26-024098 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-04-07 16:50 | 2026-04-06 | VIR | De Backer Marianne | Pres, CEO, Dir | S - Sale | $9.16 | -72.6K | 948.1K | -7% | -$664.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-06 | S | D | 72,559 | $9.16 | 948,145 | D | — | — | (F1) Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person. |